Nimbus founding CSO Rosana Kapeller leaves to explore exec role; AI startup BioXcel pockets $60M from IPO

Rosana Kapeller

→ Having helped turn “the vision of computational-based drug discovery into reality”  at Nimbus Therapeutics, founding CSO Rosana Kapeller has decided it’s time to take on an executive leadership role elsewhere. During her eight-year tenure, the Cambridge, MA-based biotech has built up a pipeline spanning metabolic, autoimmune and immuno-oncology programs. That has attracted big partners and big bucks from Gilead, Genentech and Celgene. Before joining Nimbus, Kapeller co-founded Aileron Therapeutics. “Rosana is a top-notch scientist who is uniformly admired by the team at Nimbus and our wide array of corporate and academic partners,” Nimbus CEO Don Nicholson said in a farewell statement. “She has helped assemble a talented, high caliber drug discovery organization which is larger and more capable than at any time in our history, and the deep experience and talent of our leadership team has enabled a seamless transition.”

→ AI startup BioXcel had to settle for a $60 million raise from its IPO. The biotech sold 5.4 million shares at $11 each. Underwriters have a 30-day option to purchase up to an additional 818,181 shares at that price.

Cytox and its partners at Cardiff University has been granted £800,000 ($1.3 million) by Innovate UK to further evaluate the genetic test they have developed for prodromal Alzheimer’s disease, .

With contribution from John Carroll.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->